Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Vasculitis 1Neoplasms 1Lupus Erythematosus, Systemic 1Glomerulonephritis 1COVID-19 1

Interventions

COVID-19 Vaccines 4Blood Specimen Collection 4Surveys and Questionnaires 3Standard of Care 32019-nCoV Vaccine mRNA-1273 3Pandemic Preparedness 2sotrovimab 1sinovac COVID-19 vaccine 1selinexor 1regorafenib 1proxalutamide 1monalizumab 1lenzilumab 1ciclesonide 1bemcentinib 1avdoralimab 1acalabrutinib 1XAV-19 1Surgical Procedures, Operative 1Sperm Count 1Specimen Handling 1Sorafenib 1Sodium Chloride 1Rabeprazole 1Patient Reported Outcome Measures 1Observation 1Nutritional Status 1Niclosamide 1Meopa 1Mastectomy, Segmental 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × COVID-19 × Niclosamide × Clear all
NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡